Rilzabrutinib ITP denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Step Therapy to Rilzabrutinib for ITP

Step therapy — sometimes called "fail first" — requires that a patient try and fail one or more less expensive or preferred treatments before Cigna will authorize coverage of rilzabrutinib. For ITP, this typically means demonstrating that earlier-line therapies have already been tried and have not provided adequate disease control, or that they are contraindicated or otherwise inappropriate for the individual patient. Step-therapy denials occur when the documentation submitted does not clearly establish that the required prior steps have been completed.

## Why This Denial Is Appealable

Step-therapy requirements must allow for exceptions when prior treatments have been tried and failed, are medically contraindicated, or are otherwise clinically inappropriate for a specific patient. Many states have enacted step-therapy reform laws, and federal rules under ERISA and the ACA require full-and-fair review that takes your actual clinical history into account. A step-therapy denial based on an incomplete review of your medical record is appealable.

Federal rights: - ACA §2719 / ERISA §503 — written internal appeal with specific clinical rationale. - External review after internal denial; the window is generally up to approximately four months from the denial notice — verify the exact deadline on your Explanation of Benefits. - Expedited review when standard timelines would seriously jeopardize health.

## Your Appeal Process and Timeline

1. Obtain Cigna's complete step-therapy protocol for rilzabrutinib in ITP — the specific prior drugs required and the definition of treatment failure Cigna uses. 2. Map your treatment history against each required step. 3. For any step you completed, document it with start/stop dates and outcomes. For any step you did not complete, document why (intolerance, contraindication, or clinical reason) in a prescriber letter. 4. File the internal appeal with this documentation. Request external review if denied.

## Documentation to Gather

• Prior-treatment records: for each step-therapy drug, chart notes, pharmacy records, or prescriber letters showing the drug was tried, the dates of use, and the specific reason it was stopped or deemed insufficient.
• Failure documentation: objective evidence of inadequate response (platelet records, bleeding events) or adverse effects requiring discontinuation.
• Prescriber medical-necessity letter: explains why each required step has been addressed and why rilzabrutinib is the appropriate next treatment, with reference to the applicable ASH guideline and FDA-approved prescribing information.
• Plan documents: the Summary Plan Description and any step-therapy exception criteria.

## Criteria-Mapping Structure

Create a table with each step-therapy requirement in one column and the corresponding chart evidence or prescriber explanation in the adjacent column. This format makes the clinical argument impossible to overlook and demonstrates compliance step by step. Attach the relevant chart excerpts as labeled exhibits referenced in the table.